Product Description
Our drug candidate AVX420 is a molecule that blocks the enzyme cPLA2alpha that plays a key role in the development of cancer and inflammation. AVX420 has shown promising results in several preclinical models for leukemia. What is unique about AVX420 is that the molecule attacks the cancer in multiple ways. (Sourced from: https://www.coeginpharma.com/en/our-research/projects/leukemia/)
Mechanisms of Action: cPLA2a Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Coegin
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|